机构:[1]Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院肿瘤内科临床科室[2]Medicine, Burning Rock Biotech, Guangzhou, China
第一作者机构:[1]Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China
推荐引用方式(GB/T 7714):
Wang Y.,Zuo J.,Feng L.,et al.Exploring the utility of TP53 mutations as prognostic markers in patients with non-small cell lung cancer (NSCLC)[J].ANNALS OF ONCOLOGY.2020,31:S799-S800.doi:10.1016/j.annonc.2020.08.1431.
APA:
Wang, Y.,Zuo, J.,Feng, L.,Fan, Z.,Wang, L....&Zhou, J..(2020).Exploring the utility of TP53 mutations as prognostic markers in patients with non-small cell lung cancer (NSCLC).ANNALS OF ONCOLOGY,31,
MLA:
Wang, Y.,et al."Exploring the utility of TP53 mutations as prognostic markers in patients with non-small cell lung cancer (NSCLC)".ANNALS OF ONCOLOGY 31.(2020):S799-S800